04th week of 2009 patent applcation highlights part 32 |
Patent application number | Title | Published |
20090022714 | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist - The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGFR antagonist and an EGFR antagonist. | 2009-01-22 |
20090022715 | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof - Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof. | 2009-01-22 |
20090022716 | COMBINATION METHODS OF INHIBITING TUMOR GROWTH WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR ANTAGONIST - The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation, chemotherapy, and/or an additional receptor antagonist. | 2009-01-22 |
20090022717 | ANTIBODIES THAT BIND CXCR7 EPITOPES - Antibodies that bind CXCR | 2009-01-22 |
20090022718 | Methods of treating a blood pathology using anti-TNF antibodies and fragments thereof - Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided. | 2009-01-22 |
20090022719 | Preventive and/or therapeutic method for systemic lupus erythematosus comprising anti-IL-6 receptor antibody administration - A preventive and/or therapeutic agent for systemic lupus erythematosus comprising an anti-interleukin-6 (IL-6) receptor antibody as an active ingredient. | 2009-01-22 |
20090022720 | Conjugate of an antibody against CD4 and antifusogenic peptides - The current invention is related to a conjugate comprising two or more antifusogenic peptides and an anti-CD4 antibody (mAb CD4) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CD4 antibody and to the pharmaceutical use of said conjugate. | 2009-01-22 |
20090022721 | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening. | 2009-01-22 |
20090022722 | Cytotoxicity mediation of cells evidencing surface expression of CD59 - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention. | 2009-01-22 |
20090022723 | ANTI-IL-TIF ANTIBODIES AND METHODS OF USING IN INFLAMMATION - The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed. | 2009-01-22 |
20090022724 | Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof - The present disclosure provides attractin/mahogany-like polypeptides and fragments thereof, polynucleotides encoding such polypeptides and fragments, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides or fragments, and assays and methods employing these polypeptides, antibodies, and polynucleotides. | 2009-01-22 |
20090022725 | IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders. | 2009-01-22 |
20090022726 | METHOD OF USING IL6 ANTAGONISTS WITH PROTEASOME INHIBITORS - The invention is directed to a method of treating a cancerous disorder or condition, or an IL- | 2009-01-22 |
20090022727 | INJECTABLE, NONAQUEOUS SUSPENSION WITH HIGH CONCENTRATION OF THERAPEUTIC AGENT - An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed. | 2009-01-22 |
20090022728 | METHODS OF TREATING OPHTHALMIC DISEASES - Methods of using inhibitors (including monoclonal antibodies) directed against amyloid-beta peptide for the treatment of ophthalmic diseases such as age-related macular degeneration are described. | 2009-01-22 |
20090022729 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS - The present invention provides methods and pharmaceutical compositions for treating or preventing cardiac dysfunctions (e.g., cardiac hypertrophy, cardiac remodeling, or heart failure) in subjects who have or are likely to develop cardiomyopathies. Some of the methods are directed to therapeutic or prophylactic treatment of cardiac dysfunctions in subjects having undergone myocardial injuries such as cardiac ischemia/reperfusion or myocardial infarction. Typically, these methods comprising administering to the subjects a therapeutic composition comprising a compound which can specifically inhibit PAR1 mediated signaling or down-regulate the cellular level of PAR1. | 2009-01-22 |
20090022730 | METHODS AND COMPOSITIONS FOR ASSESSING ACUTE REJECTION - The invention relates to the analysis and identification of genes that are up-regulated simultaneously in transplant rejection. This simultaneous up-regulation of genes provides a molecular signature to accurately detect transplant rejection. | 2009-01-22 |
20090022731 | Arthritis-associated B cell gene expression - The invention features methods and compositions benefiting from differential gene expression observed in arthritis-associated B cells. | 2009-01-22 |
20090022732 | Crystal of a cytochrome-ligand complex and methods of use - The teachings relates to the three-dimensional structure of a crystal of a cytochrome protein complexed with a ligand. The three-dimensional structure of four cytochrome P450 2A6-ligand complexes are disclosed. Cytochrome P450 2A6-ligand crystal structures, wherein the ligand is an inhibitor molecule, are useful for providing structural information that may be integrated into drug screening and drug design processes. Thus, the teachings also relate to methods for utilizing a crystal structure of a cytochrome P450 2A6-ligand complex for identifying, designing, selecting, or testing inhibitors of the cytochrome protein. Such inhibitors are useful as therapeutics for the treatment or modulation of i) diseases; ii) disease symptoms; or iii) the effect of other physiological events mediated by the cytochrome. | 2009-01-22 |
20090022733 | Methods for treating Disease with an IL-1R antibody - The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-1 by administering an IL-1 antagonist, such as soluble type II IL-1 receptor. | 2009-01-22 |
20090022734 | USE OF EPO RECEPTOR ACTIVATION OR STIMULATION FOR THE IMPROVEMENT OF THE EDSS SCORE IN PATIENTS WITH MULTIPLE SCLEROSIS - The invention provides a method of improving the expanded disability status scale (EDSS) score achieved by mammals affected by multiple sclerosis in which a substance effecting increased and/or prolonged activation and/or stimulation of the erythropoietin (EPO) receptor is administered to the mammal. In certain embodiments, the substance is administered in intervals which are interrupted by application-free periods of time in which said substance is not administered. | 2009-01-22 |
20090022735 | Receptor Binding Polypeptides - Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed. | 2009-01-22 |
20090022736 | Monoclonal Antibodies That Specifically Bind To And Neutralize Bacillus Anthracis Toxin, Compositions, And Methods Of Use - The invention features compositions relating to antibodies that specifically bind to the protective antigen of | 2009-01-22 |
20090022737 | ALDOS AS MODIFIERS OF THE IGF PATHWAY AND METHODS OF USE - Human ALDO genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of ALDO are provided. | 2009-01-22 |
20090022738 | Multispecific deimmunized CD3-binders - The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmacutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention. | 2009-01-22 |
20090022739 | MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR ALPHA (tnf-ALPHA) AND TREATING HUMAN DISEASE OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-ALPHA - Blocking the voltage-gated potassium channel Kv1.1 of T-cells causes the robust and exclusive production of TNF-α, and thus can be used for eradication of cancer, improved eradication of infectious organisms, increased permeability of blood vessels and the blood brain barriers to given molecules and cells, and improved neuronal features, regeneration function and development. Blocking the voltage-gated potassium channel Kv1.1 of T-cells causes the robust and exclusive production of TNF-α. Similarly, unblocking of a blocked Kv1.1 channel or opening of a Kv1.1 channel will prevent the T-cells from producing and secreting excess amounts of TNF-α, thus being useful in the treatment of conditions such as rheumatoid arthritis and for treating neurological diseases associated with defected functioning and/or pathological block of the Kv1.1 channel, among them PNH associated with Kv1 Abs; Encephalitis associated with Kv1 Abs; and Episodic-ataxia type 1 (EA-1), in all of which the T-cell blocked Kv1.1 channel may secrete excess TNFa and thereby contribute to the pathology. Blocking of the Kv1.1 channel may be achieved in vivo or ex vivo by contact with a selective Kv1.1 channel blocking molecule such as Dendrotoxin-K or a selective monoclonal antibody against the Kv1.1 channel. Preventing the Kv1.1. block would be achieved by Kv1.1 openers, or by molecules that would prevent the closure of the Kv1.1 channel. | 2009-01-22 |
20090022740 | NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE - Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment. | 2009-01-22 |
20090022741 | NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE - Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment. | 2009-01-22 |
20090022742 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS - Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more | 2009-01-22 |
20090022743 | Peptides Effective in the Treatment of Tumors and Other Conditions Requiring the Removal or Destruction of Cells - The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein. | 2009-01-22 |
20090022744 | Modified Fc molecules - The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. | 2009-01-22 |
20090022745 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof - Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof. | 2009-01-22 |
20090022746 | Complexes for transferring nucleic acids into cells - The invention relates to complexes of cationic polymers and nucleic acids, to the use of such complexes for introducing nucleic acids into cells and organisms, to the use of the complexes as pharmaceuticals, and to novel polymers which can be used to prepare the complexes. | 2009-01-22 |
20090022747 | B7-H3 AND B7-H4, NOVEL IMMUNOREGULATORY MOLECULES - The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 2009-01-22 |
20090022748 | Unique associated Kaposi's sarcoma virus sequences and uses thereof - This invention provides an isolated peptide encoded by a nucleic acid which is at least 30 nucleotides in length and has a sequence which uniquely defines a herpesvirus associated with Kaposis' sarcoma, which herpesvirus is present in and recoverable from the HBL-6 cell line (ATCC Accession No. CRL 11762). | 2009-01-22 |
20090022749 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 2009-01-22 |
20090022750 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 2009-01-22 |
20090022751 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 2009-01-22 |
20090022752 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 2009-01-22 |
20090022753 | Surface proteins of streptococcus pyogenes - β-hemolytic streptococci polynucleotides, polypeptides, particularly | 2009-01-22 |
20090022754 | Recombinant antigen for diagnosis and prevention of murine typhus - The invention relates to a recombinant immunogenic composition from | 2009-01-22 |
20090022755 | VACCINES AGAINST CHLAMYDIAL INFECTION - The present invention relates to compositions comprising proteins or polynucleotides of | 2009-01-22 |
20090022756 | Recombinant F1-V Plague Vaccine - Disclosed herein is a composition comprising a purified fusion protein comprising all or part of F1 antigen of | 2009-01-22 |
20090022757 | Method for treating photoreceptor cell degeneration - The present invention provides a method for treating photoreceptor cell degeneration in a mammal. The method includes orally administering a composition comprising germination activated sporoderm-broken | 2009-01-22 |
20090022758 | Yeast cell walls for the treatment or prevention of hyperglycemia or for the stabilization of glycemia - The invention relates to agents and preparations for the treatment or prevention of hyperglycemia, or for the stabilization of glycemia, based on the cell walls of yeast and preparation of a corresponding therapeutic composition. | 2009-01-22 |
20090022759 | ADENOVIRUS VECTOR AND METHOD TO MANIPULATE THE ADENOVIRUS GENOME - Adenoviruses (Ads) and vectors derived thereof have been used for somatic gene therapy, gene therapy of cancer and gene therapy of infectious diseases/vaccination. To date, almost all trials are based on the well established Ad5-based vectors. Pre-existing immunity and the limited targeting specificity of Ad5 makes it desirable to exploit new Ad serotypes for these therapeutic avenues. This is hampered by the limited number of cloned Ad genomes and the difficulty to manipulate them genetically. We describe an isolated adenovirus, and/or a variant adenovirus that is optionally modified to include a heterologous nucleic acid molecule and pharmaceutical compositions comprising said adenovirus. This adenovirus has a lower pre-existing immunity and exhibits interesting targeting activities for a variety of tissues and cells, and may be particularly useful for transduction of dendritic cells and other leukocytes and or leukocyte based tumours. We also describe new methods to clone and manipulate adenoviral genomes. | 2009-01-22 |
20090022760 | Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants - The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen. | 2009-01-22 |
20090022761 | Enhancement of Immune Response to Vaccine by Interferon Alpha - Exogenous cDNA capable of expressing interferon″ activity, exogenous interferon″ protein, inducers of endogenous interferon″ protein activity, inducers of endogenous interferon $ protein activity, inducers of endogenous interferon′ activity, or inducers of other immune-enhancing activity can be combined with a vaccine to enhance an immune response. Specifically disclosed are adjuvant and vaccine combinations where the adjuvant comprises a cDNA capable of expressing interferon″ activity, a complex comprising polyriboinosinic-polyribocytidilic acid, or a complex comprising polyriboinosinic-polyribocytidilic acid, poly-L-lysine, and carboxymethylcellulose and where the vaccine is a live vaccine virus derived from a virus causing porcine reproductive and respiratory syndrome disease. | 2009-01-22 |
20090022762 | Polyvalent influenza virus-like particle (VLP) compositions - Polyvalent influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these polyvalent VLPs as well as methods of making and using these VLPs. | 2009-01-22 |
20090022763 | ANIMAL PRODUCT FREE MEDIA AND PROCESSES FOR OBTAINING A BOTULINUM TOXIN - Media and processes for the fermentation of | 2009-01-22 |
20090022764 | ORGANIC COMPOUNDS - The present invention refers to a process for the production of controlled-release aqueous compositions comprising an active ingredient releasably contained within polymeric particles. The polymeric particles are obtainable by ring-opening metathesis polymerisation of a monomer of the general formula (I) | 2009-01-22 |
20090022765 | COSMETIC PIGMENT COMPOSITION CONTAINING GOLD OR SILVER NANO-PARTICLES - The present invention relates to a cosmetic pigment composition exhibiting colors in the visible region, which comprises an effective amount of nanoparticles or a mixture of two or more nanoparticles selected from the group consisting of (a) gold nanoparticles exhibiting red color; (b) silver nanoparticles exhibiting yellow color; (c) gold-silver alloy nanoparticles exhibiting flame color; and (d) gold nanoparticles exhibiting blue color, and a color cosmetic composition and a color lotion comprising the pigment composition. According to the present invention, it is possible to prepare pigments exhibiting various colors in the visible region using gold or silver nanoparticles, and a cosmetic pigment composition which can exhibit various colors by mixing the pigments in various compositional ratios, in which precipitation or agglomeration of particles does not occur, and whose color can be maintained for a long time. Also, since the pigment of the present invention is not harmful to the human body unlike conventional metal pigments, and contains gold or silver that is beneficial to health, the pigment can be used in various applications as functional raw materials. | 2009-01-22 |
20090022766 | METAL-ENHANCED FLUORESCENCE NANOPARTICLES - The present invention relates to nanoparticles comprising a metallic core with a surface coating, wherein the coating comprises at least an excitable radiative molecule attached thereto or impregnated therein, and wherein the excitable molecule is positioned at a sufficient distance from metallic core to enhance emissions when excited. The nanoparticles are included in compositions that may be used for surface coatings, cosmetics, assays, flow velocity measurements and targeting of tissue. | 2009-01-22 |
20090022767 | COMPOSITION, DEVICE AND METHOD FOR TRANSDERMAL DELIVERY OF INSECT REPELLENT - A composition, device and method for the transdermal delivery of effective amounts of insect repellent provide a transdermal patch having a backing layer formed of a breathable, skin-like material such as urethane, a removable liner layer and a drug formulation and adhesive disposed between the backing layer and the liner layer. The drug formulation includes Vitamin B1 which is a thermally diffusible insect repellant, and aloe vera which accelerates the diffusion of the Vitamin B1 into a wearer's skin and bloodstream. The liner layer is removed and the patch affixed to a wearer's skin by means of the adhesive, and repels insect bites for 36 hours or more. | 2009-01-22 |
20090022768 | Continuous flow chamber device for separation, concentration, and/or purification of cells - The present invention relates to methods and apparatuses for neutralizing cancer cells. In particular, the invention relates to separating of cancer cell type from a mixture of different cell types based on the differential rolling property of cancer cell on a substrate coated with a first molecules that exhibits adhesive property with the particular cell type and neutralizing the cancer cell by a second molecule that is also coated on the substrate. This technology is adaptable for use in vivo, in vitro, or ex vivo tumor neutralization. | 2009-01-22 |
20090022769 | Medical Devices Comprising Polymeric Drug Delivery Systems With Drug Solubility Gradients - Disclosed are drug delivery systems comprising drugs admixed with polymers having drug solubility gradients and methods of making the polymers. Also disclosed are medical devices having coatings thereon comprising the drug solubility gradient-containing polymers and at least one drug. | 2009-01-22 |
20090022770 | Chitosan Compositions - This invention relates to an orthopaedic composition comprising porous chitosan particles suspended in a liquid medium wherein the liquid medium further comprises a biocompatible polymer. The invention also provides a process for preparing a solid or semi-solid orthopaedic material by drying the orthopaedic composition. The resulting solid or semi-solid orthopaedic material finds use as a bone-replacement material, a bone cement and a tissue scaffold. A process for preparing suitable porous chitosan particles for the present invention by incorporating a porogen capable of including crystallinity is also described. | 2009-01-22 |
20090022771 | BIOMATERIAL - A process for the preparation of a composite biomaterial comprising an inorganic material and an organic material, the process comprising: (a) providing a first slurry composition comprising a liquid carrier, an inorganic material and an organic material; (b) providing a mould for the slurry; (c) depositing the slurry in the mould; (d) cooling the slurry deposited in the mould to a temperature at which the liquid carrier transforms into a plurality of solid crystals or particles; (e) removing at least some of the plurality of solid crystals or particles by sublimation and/or evaporation to leave a porous composite material comprising an inorganic material and an organic material; and (f) removing the material from the mould. | 2009-01-22 |
20090022772 | BIOABSORBABLE ELASTOMERIC ARTERIAL SUPPORT DEVICE AND METHODS OF USE - The invention provides bioabsorbable elastomeric arterial support devices fabricated using elastomeric polymer networks and semi-interpenetrating networks in which a linear polymer is crosslinked by ester or alpha-amino-acid containing cross-linkers that polymerize upon exposure to active species. The invention devices are designed for implant into curved segments of artery and can be expanded during arterial implant and cross-linked in vivo in the expanded state to restore a clogged artery to extended function. The invention devices are useful for in vivo implant in diseased arteries and for delivery of a variety of therapeutic molecules in a time release fashion to surrounding tissues to reduce or eliminate arterial response to implant of the device. | 2009-01-22 |
20090022773 | POROUS AND BIOCOMPATIBLE CARRIER MATERIAL FOR TREATING BONE AND/OR CARTILAGE DEFECTS - A porous and biocompatible carrier material for treating bone and/or cartilage defects, including a collagen of animal origin that has an active substance complex. | 2009-01-22 |
20090022774 | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances for treatment of vascular disorder - A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, | 2009-01-22 |
20090022775 | POLYMER BACKBONE FOR PRODUCING ARTIFICIAL TISSUE - The invention relates to polymer scaffolds suitable for producing artificial tissues, in particular polysaccharide scaffolds, to processes for their preparation, to their use for producing artificial tissues, and to artificial tissues produced on the basis of such polymer scaffolds. | 2009-01-22 |
20090022776 | COMPOSITION AND METHOD FOR TREATMENT AND PREVENTION OF RESTENOSIS - Compositions and methods are disclosed which employ PARIS proteins that are useful for suppressing proliferation of smooth muscle cells. Preferred PARISs are soluble proteins that are secreted by vascular smooth muscle cells, and include PARIS-1 (neuronal pentraxin 1), PARIS-2 (SBP (MIC-1, GDF-15), PARIS-3 (BTG2) and PARIS-4 (soluble fractalkine). Methods of preventing or treating restenosis by administering the new compositions are disclosed. Also disclosed are methods for treating patients undergoing angioplasty procedures, patients with atherosclerosis, and patients with other proliferative disorders, in order to suppress the growth of vascular smooth muscle cells or other cells that play a role in the particular proliferative disorder or condition. A method of screening mRNAs and identifying genes encoding PARISs is also disclosed. | 2009-01-22 |
20090022777 | Methods for progenitor cell recruitment and isolation - The invention relates to the use of one or more growth factors in a drug delivery system, optionally with an external mesh housing, to recruit and optionally harvest progenitor cells. These cells include those that normally reside in the bone marrow. | 2009-01-22 |
20090022778 | EXTERNAL PLASTER CONTAINING FLURBIPROFEN - In a plaster for external use for transdermal absorption in which an adhesive layer is laminated on a plastic backing, the adhesive layer contains a styrene-isoprene-styrene block copolymer (SIS), a tackifying resin and a softener which are essential ingredients, and further contains flurbiprofen blended as an active ingredient. The present plaster for external use is a flurbiprofen containing plaster for external use enabling long-term stable release of contained flurbiprofen, and having excellent stability and very high drug releasing property. | 2009-01-22 |
20090022779 | Phenytoin Formulations, and Uses Thereof in Wound Healing - A formulation of phenyloin suitable for topical application to a wound comprises a reservoir of phenyloin entrapped within a stabilising matrix, and an amount of dissolved phenyloin, wherein the dissolved phenyloin is in chemical equilibrium with the phenyloin entrapped within the stabilised matrix. The stabilised matrix may comprise a gel matrix, especially a gel matrix in which the polymer of the gel forms ion-pairs with the phenyloin. Also described are methods of treating a wound in diabetic and non-diabetic patients using a formulation according to the invention. | 2009-01-22 |
20090022780 | HYDROGEL - The invention is related to gel preparations capable of absorbing as well as releasing liquid, and the use of such gel preparations in the treatment of wounds. | 2009-01-22 |
20090022781 | DELIVERY MEANS - A delivery means, for example a dressing, for delivering an antibacterial metal, for example silver, comprises the metal in combination with a hydrophilic polymer. The polymer may be cross-linked by a butylidene polymer to define a gel. In the examples, silver nitrate may be reduced to metallic silver, protected using polyvinylalcohol which is cross-linked to define a gel. | 2009-01-22 |
20090022782 | Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue - A phospholipid derivative useful for the preparation of liposomes for efficient uptake of an antitumor agent or a gene intracellularly by a target tumor cell, which comprises a residue of an alcohol compound and a residue of a phospholipid, and comprising a peptide between the residue of an alcohol compound and the residue of a phospholipid, and wherein (a) the alcohol compound is an alcohol compound selected from poly(alkylene glycols) and the like, (b) the phospholipid is a phospholipid selected from phosphatidylethanolamines, phosphatidylcholines, phosphatidylserines and the like, and (c) the peptide is a peptide comprising a substrate peptide that can serve as a substrate of a matrix metalloproteinase, provided that one amino acid residue or an oligopeptide containing 2 to 8 amino acid residues may bind to one or both ends of the substrate peptide. | 2009-01-22 |
20090022783 | siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES - The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally. | 2009-01-22 |
20090022784 | SYSTEMS, DEVICES, AND METHODS FOR IONTOPHORETIC DELIVERY OF COMPOSITIONS INCLUDING LIPOSOME-ENCAPSULATED INSULIN - Systems, devices, and methods for delivering one or more active ingredients to intradermal tissues, deep regions of pores, and intradermal tissues in the vicinity of pores. In some embodiments, a composition is provided including a plurality of liposomes including a cationic lipid, and an amphiphilic glycerophospholipid having a saturated fatty acid moiety and an unsaturated fatty acid moiety, and at least one insulin, insulin analog, or insulin derivative. | 2009-01-22 |
20090022785 | Permeable Capsules - The present invention relates to permeable capsules comprising at least one cell comprising a recombinant nucleic acid molecule with a heat inducible promoter operably linked to a nucleic acid encoding for a protein, a peptide or a functional nucleic acid molecule and at least one heat emitting agent capable to emit heat when exposed to electromagnetic radiation or to a magnetic field. | 2009-01-22 |
20090022786 | Oral pharmaceutical dosage form and manufacturing method thereof - The present invention provides an coated oral pharmaceutical dosage form comprising a composition of a non-steroidal anti-inflammatory drug (NSAID) as multilayered spherical granule combined with a composition of prostaglandin, and a film coating. The present invention also provides a method for manufacturing the dosage form, which comprising the steps of preparing the compositions of NSAID and prostaglandin separately, combing the compositions to form a pharmaceutical dosage form, and coating the dosage form with a film coating. | 2009-01-22 |
20090022787 | PHARMACEUTICAL COMPOSITION COMPRISING 11-DEOXY- PROSTAGLANDIN COMPOUND AND METHOD FOR STABILIZING THE COMPOUND - Provided is a pharmaceutical composition comprising a 11-deoxy-prostaglandin compound represented by formula (I): | 2009-01-22 |
20090022788 | DIETARY SUPPLEMENT FOR HEALING OR REGRESSING SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE, GASTRITIS AND ULCERS - The current invention presents a dietary supplement obtained from a mixture of melatonin, vitamins and aminoacids for healing or regressing symptoms of gastroesophageal reflux disease (such as heartburn, regurgitation, dysphagia, coughing, hoarseness, chest pain and odynophagia), gastritis and several types of ulcerations. | 2009-01-22 |
20090022789 | ENHANCED FORMULATIONS OF LAMOTRIGINE - A once-a-day, extended-release formulation of lamotrigine, exhibiting a significantly similar release rate throughout the GI tract irrespective of the pH of the environment, is provided. The formulation comprises lamotrigine, an organic acid, a release enhancing polymer and a release controlling polymer. The use of the formulation for the treatment of the neurological disorders is also disclosed. | 2009-01-22 |
20090022790 | TAMPER RESISTANT CO-EXTRUDED DOSAGE FORM CONTAINING AN ACTIVE AGENT AND AN ADVERSE AGENT AND PROCESS OF MAKING SAME - The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. | 2009-01-22 |
20090022791 | Porous cellulose aggregate and molding composition thereof - A porous cellulose aggregate characterized by having a secondary aggregate structure resulting from aggregation of primary cellulose particles, having a pore volume within a particle of 0.265 to 2.625 cm | 2009-01-22 |
20090022792 | Vitamin D content uniformity in pharmaceutical dosage forms - New dosage forms of vitamin D and calcium carbonate having improved content uniformity are described. The improvements are realized through modifications to the formulation, the raw material specifications, and the process of manufacture. | 2009-01-22 |
20090022793 | MESALAMINE SUPPOSITORY - The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5. | 2009-01-22 |
20090022794 | Topiramate Tablet Formulation - The invention provides pharmaceutical compositions comprising as active ingredient topiramate, which are suitable for manufacturing tablet formulations by direct compression. The compositions preferably comprise spray-dried granulated mannitol and provide tablets of desired friability and hardness. | 2009-01-22 |
20090022795 | Stable Pharmaceutical Formulation of an Acid Labile Compound and Process for Preparing the Same - The disclosed invention provides oral pharmaceutical formulations of an acid labile benzimidazole derivative comprising (a) a core comprising an acid labile benzimidazole derivative, (b) a seal coating layer, and (c) an enteric coating layer, wherein the core of the composition is devoid of any disintegrant. | 2009-01-22 |
20090022796 | Novel Substituted Benzimidazole Dosage Forms and Method of Using Same - The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical composition consisting of a proton pump inhibitor, including preparations of s-omeprazole, and at least one buffering agent. Also provided is a pharmaceutical composition comprising a parietal cell activator, an anti-foaming agent, a flavoring agent and combinations thereof; a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical composition; and a kit for the preparation of a liquid oral pharmaceutical composition. Dosage forms include: liquid, powder, tablet, capsule, effervescent powder, effervescent tablet, pellets, and granules | 2009-01-22 |
20090022797 | Stabilized tolterodine tartrate formulations - A pharmaceutical composition contains tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used to make various types of immediate release and controlled release dosage forms. | 2009-01-22 |
20090022799 | COMPOSITIONS THAT CONTAIN BETA-GLUCAN TO BE USED FOR THE PREVENTION AND TREATMENT OF DISEASE AND METHODS FOR THEIR USE - This application for patent discloses β-Glucan containing compositions, dosage forms, delivery methods, and techniques for the purposes of preventing and treating mucositis through wound healing and tissue re-organization, as well as the treatment of immune disorders such as Alzheimer's disease, Multiple Sclerosis and Parkinson's disease. β-Glucan containing compositions, dosage forms and methods to deliver therapeutic and prophylactic vaccines and anti-cancer drugs are also disclosed, as are methods to stabilize a drug to enhance its shelf life and to enhance the level and duration of its bioactivity. | 2009-01-22 |
20090022800 | Coating for small bodies - Coated bodies and a process, apparatus and article of manufacture for coating bodies in a non-fluidized state, including tablets, by producing an upward spray of coating fluid by means of a two-fluid nozzle as defined herein and contacting said bodies with said spray of coating fluid in a non-fludized state; wherein, before contacting the bodies with said spray, providing the bodies with a spinning movement by acentral impact of gas jets directed upward to intersect the centerline of said spray; guiding the spinning bodies by said gas jets towards a central position over the two-fluid nozzle, thereby increasing the number of suspended bodies contacting the spray; providing atomization gas to the two-fluid nozzle in an amount less than the one which after moderation by means of muffling gas would scatter the bodies in the spray zone; and pneumatically muffling the atomization gas just above the nozzle to reduce the spray body scattering effect thereof. | 2009-01-22 |
20090022801 | Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms - Methods are provided for promoting the healing of tissue of a multicellular organism. The methods can include administering a therapeutically effective amount of a polysulfonated material in a liquid mixture to reduce one or both of inflammation and cancerous cell growth. The methods may alternatively or additionally include internally administering a therapeutically effective amount of a polysulfonated material associated with a solid material to reduce one or both of inflammation and cancerous cell growth. Compositions for healing the tissue of a multicellular organism are provided that can include a sulfonated material in a liquid mixture, as well as solid particles. | 2009-01-22 |
20090022802 | CARDIOMYOPATHY THERAPEUTIC AGENT - The present invention provides a cardiomyopathy therapeutic agent that contains hepatocyte growth factor (HGF) and gelatin hydrogel, and gradually releases HGF, which is useful in treating cardiomyopathy. | 2009-01-22 |
20090022803 | Oral Formulations For Delivery of Catecholic Butanes Including Ndga Compounds - The present invention provides for compositions, kits and methods for treatment of diseases, where the compositions contain catecholic butanes, including NDGA compounds, such as NDGA derivatives, for example tetra-O-methyl NDGA. The present invention also provides for solubilizing agents and excipients that are suitable for administration of the present compounds into animals via an oral route, whether in a liquid, semi-solid or solid form. | 2009-01-22 |
20090022804 | CHEMOEMBOLISATION - A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin. | 2009-01-22 |
20090022805 | Polypeptide microparticles having sustained release characteristics, methods and uses - The invention provides polypeptide microparticles having control release features, particular methods for the preparation of such microparticles, and drug delivery systems that include polypeptide microparticles. | 2009-01-22 |
20090022806 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof - Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed. | 2009-01-22 |
20090022807 | Drug formulations having inert sealed cores - A drug composition comprising a coated bead is used in the manufacture of immediate release and/or controlled release drug compositions. In a specific embodiment, the bead includes an inert core of a water-soluble or water-swellable material, which has been coated with a seal layer formed from a non-polymeric hydrophobic material. The immediate and/or controlled release beads may be used to form tablets or capsules. A method of making the beads by sequential deposition of multiple layers on the inert cores is also described. | 2009-01-22 |
20090022808 | Coated Hyaluronic Acid Particles - The present invention generally relates to particles comprising hyaluronic acid, wherein the particles are coated or encapsulated with a coating. The coating preferably comprises a polymer, protein, polysaccharide, or combination thereof that decreases the rate of degradation of the hyaluronic acid once the particles are placed in an aqueous environment, such as inside mammalian skin. The compositions of the present invention comprising such coated hyaluronic acid are useful for soft tissue augmentation, and are particularly useful as dermal fillers. | 2009-01-22 |
20090022809 | STABLE TASTE MASKED FORMULATIONS OF CEPHALOSPORINS - A stable taste masked, pharmaceutical composition comprising a plurality of coated, non-disintegrating discrete dosage units, said units comprising of a core comprising one or more cephalosporins such as cefuroxime axetil and cefpodoxime proxetil and one or more coating layers. Cefuroxime axetil is in α-crystalline and amorphous forms, where at least 30% of the Cefuroxime axetil is in the α-crystalline form, wherein the particle size distribution of the α-crystalline form being such that 100% of the particles have a particle size below 250μ. The ratio of the crystalline fraction to the amorphous fraction ranges from 0.3:0.7 to 0.99:0.01. The particle size of cefpodoxime proxetil is such that 90% of the particles are below 15μ. The process of preparation of coated, non-disintegrating pellets comprising the steps of reducing the particle size of the one or more cephalosporins, blending with the other excipients, wet granulation, extrusion, spheronization, drying and screening to obtain pellets, said pellets being further coated with one or more layers of film coating to achieve taste masking. | 2009-01-22 |
20090022810 | EmunoTM Bar, by Nutra-ShieldTM - The invention, Emuno Bar by NutraShield, is a nutraceutical food bar composed of all natural ingredients that are rich in antioxidants and fortified with the patented Formulation 100 (U.S. Pat. No. 6,667,063, B2). The invention is a dedicated delivery system for U.S. Pat. No. 6,667,063, B2 and designed to boost the human immune system. The Emuno Bar will be the only Dark Chocolate covered functional food bar containing the new revolutionary patented Formulation 100. | 2009-01-22 |
20090022811 | Mineralized guided bone regeneration membranes and methods of making the same - The present invention provides a method for mineralizing commercially available guided bone regeneration membranes. The method comprises the steps of (a) providing a commercially available guided bone regeneration membrane, (b) applying a mineralizing solution, and (c) microwaving the membrane. The method may further comprise (d) rinsing the membrane in a solution such as distilled water and (e) drying the membrane. The mineralizing solution may be a solution capable of supplying or delivering a mineral such as calcium or zinc. The invention further provides guided bone regeneration membranes made by the methods described. The guided bone regeneration membrane comprises a mineral, such as, for instance calcium or zinc at a weight percent of at least 5%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20% or at least 25% (weight percent) of the membrane. Further, the invention provides methods for enhancing bone regeneration and methods for inhibiting bacterial infection and inflammation. | 2009-01-22 |
20090022812 | Liquid detergent composition - A liquid detergent composition containing (a) hydrogen peroxide or a compound for forming hydrogen peroxide in water, (b) a compound selected from boric acid, borax, a boric acid salt in an amount of from 0.05 to 1% by mass as a boron atom, (c) a compound having one or more sites, the site having one hydroxyl group at each of both sides of adjacent carbon atoms, in an amount of from 3 to 35% by mass, (d) a surfactant in an amount of from 4 to 45% by mass, and (e) water, wherein the molar ratio of the component (c)/the component (b) is from 1.5 to 2.7, and wherein the detergent composition has a pH at 20° C. of from 4.6 to 7.0. | 2009-01-22 |
20090022813 | COMPOSITION FOR IMPROVING MEMBRANE COMPOSITION AND FUNCTIONING OF CELLS - It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises
| 2009-01-22 |
20090022814 | CANCER TREATMENT METHOD - Invented is a method of treating cancer in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a TPO cell cycle activator and a chemotherapeutic agent to such mammal. | 2009-01-22 |